SVRA
NASDAQ · Biotechnology
Savara Inc
$4.96
-0.20 (-3.88%)
Open$5.14
Previous Close$5.16
Day High$5.20
Day Low$4.91
52W High$7.01
52W Low$1.89
Volume—
Avg Volume1.63M
Market Cap1.16B
P/E Ratio—
EPS$-0.53
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+1,169.0% upside
Current
$4.96
$4.96
Target
$62.94
$62.94
$52.50
$62.94 avg
$80.97
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 135.25M | 127.87M | 115.53M |
| Net Income | 19.67M | 13.91M | 14.59M |
| Profit Margin | 14.5% | 10.9% | 12.6% |
| EBITDA | 27.67M | 31.26M | 23.85M |
| Free Cash Flow | 12.49M | 17.00M | 15.12M |
| Rev Growth | +10.1% | -5.7% | +15.6% |
| Debt/Equity | 0.38 | 0.46 | 0.53 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |